ABL Bio Receives FDA Approval for Phase 1 IND of Bispecific Antibody ADC in the US
ABL Bio, a biotechnology company specializing in bispecific antibodies, has announced that its bispecific antibody ADC candidate is entering the clinical stage in the United States.
On January 19, ABL Bio stated that the Investigational New Drug (IND) application for ABL206 (NEOK001) to conduct a Phase 1 clinical trial was approved by the U.S. Food and Drug Administration (FDA) on January 16 (local time).
ABL206 is a first-in-class bispecific antibody-drug conjugate (ADC) that simultaneously targets B7-H3 and ROR1, with a topoisomerase I inhibitor attached via a linker. This candidate is the first among ABL Bio's next-generation ADC pipeline to enter the clinical stage.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Neok Bio, ABL Bio's U.S.-based subsidiary specializing in bispecific antibody ADCs, plans to initiate a Phase 1 clinical trial of ABL206 in the first half of this year. The company also announced plans to release the initial clinical results by 2027.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.